The commentators note that around 90% of both treatment groups had ER-high disease “which constrains the applicability of the data to patients with moderately ER-positive disease.”

“Among younger patients, median survival increased on the order of 4 to 5 months.

And cancer patients who received chemotherapy had a significant 1.31-fold increased fracture risk at 1 to less than 5 years after diagnosis compared with those who did not receive chemotherapy.

Clinically fit older women with early breast cancer are more likely to experience a chemotherapy-induced decline in frailty status if they have high pretreatment levels of interleukin-6 and C-reactive protein, research shows.

Patients will then be categorized as either fit, vulnerable, or frail.

A geriatric risk index based on readily available clinical factors can identify older adults with cancer who are most at risk for severe COVID-19, researchers report in The Lancet Healthy Longevity .

Incorporating geriatric assessment-guided management into the care of older patients receiving anticancer therapy could reduce the risk for treatment toxicity and falls as well as polypharmacy, suggests a cluster randomized controlled trial.

The objective response rate was 32.2% among the 276 response-evaluable NSCLC patients, 39.3% among the 280 melanoma patients, and 26.2% among the 126 with genitourinary tumors.

A geriatric assessment-driven intervention may reduce the risk for grade 3 or higher chemotherapy-related toxicities in older people with cancer, research suggests.

Methods which may be employed to detect and optimise these factors include geriatric assessment and exercise intervention.

Nonmetastatic castration-resistant prostate cancer patients aged 80 years and older benefit from treatment with second-generation androgen receptor inhibitors, suggests a pooled analysis of three trials.

US researchers have developed the Cancer and Aging Research Group–Breast Cancer score to help predict grade 3–5 chemotherapy-related toxicities in older patients with early-stage breast cancer.

Older patients with non-small-cell lung cancer who have not progressed on platinum-based doublet therapy do not gain an overall survival advantage if treated with switch maintenance therapy rather than observation, study findings show.

A database analysis indicates that adjuvant chemotherapy may prolong overall survival in patients aged at least 70 years with node- and estrogen receptor-positive breast cancer and multiple comorbidities.

A phase 2 trial suggests that low-dose erlotinib has clinical activity and a favorable safety profile among older and frail non-small-cell lung cancer patients with EGFR activating mutations.

Carboplatin–pemetrexed plus pemetrexed maintenance is noninferior to docetaxel for the first-line treatment of advanced non-small-cell lung cancer in patients aged 75 years or older, suggests a phase 3 Japanese study.

The guidelines include advice on shared-decision making between patients and healthcare professionals, the diagnosis criteria for CRF, and screening and risk assessment for the condition, including specialist advice for the care of elderly patients.

High BMI and normal albumin levels are associated with a reduced risk for grade 3 or higher chemotherapy-related toxicities among older patients, research indicates.

The Gleason score was available for 18,665 cases, and analysis of these patients showed a significant association between age and Gleason score, such that older age at diagnosis correlated with a higher Gleason score at diagnosis.